Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons

Abstract

Spanish

French

Objective:

To review clinical data on bone ossification agents that may be considered for use in the treatment of osteoporosis and osteopenia in HIV-infected patients.

Data Sources:

A literature search was performed using MEDLINE (1950-January 2008), EMBASE, PubMed, and abstracts from major HIV conferences (February 2001-October 2007). These searches were limited to human data published in English and used the key words bisphosphonates, calcitonin, raloxifene. teriparatide, HAART, osteopenia, osteoporosis, and HIV/AIDS. Additional articles were retrieved from citations of selected references.

Study Selection and Data Extraction:

Relevant information on the pharmacology, pharmacokinetics, safety, and efficacy of available treatment with hormonal and nonhormonal agents was selected. Greater emphasis was placed on randomized clinical trials than on retrospective studies.

Data Synthesis:

Osteoporosis in HIV-infected persons is at least as prevalent as in postmenopausal women, yet this population is not listed in primary care guidelines as one that should be considered for screening. In addition to bisphosphonates, calcitonin, raloxifene, and teriparatide are used to treat bone disorders. Three clinical trials to date have evaluated the use of a bisphosphonate in HIV-infected persons. The trials showed a marked increase in bone mineral density in patients taking alendronate versus those in the control groups (with/without calcium, exercise, and/or vitamin D in 1 or both arms). Dosing restrictions complicate the use of these agents; diet, exercise, and calcium supplementation remain the foremost recommended strategies to prevent bone loss. The use of estrogen, testosterone, calcitonin, and teriparatide is less studied in HIV-positive patients, but may be considered in select cases. There are some investigational drugs and agents not available in the US; however, there are not enough data to support their use.

Conclusions:

Alendronate appears to be a promising treatment option for HIV-infected patients with osteoporosis and osteopenia. Further research is required to determine the safety and efficacy of other available drugs. Until additional information is provided, and with available knowledge on the metabolism profiles of antiretroviral and bone ossification agents, alendronate appears to be the preferred agent to use in this population.

Keywords

antiretrovirals bisphosphonates HIV/AIDS osteopenia osteoporosis

Get full access to this article

View all access options for this article.

References

Armosa

, Tebas

. Bone disease and HIV infection. Clin Infect Dis 2006;42:108–14. DOI 10.1086/498511

Annapooma

, Venkateswara

, Reddy

et al. An increased risk of steoporosis during acquired immunodeficiency syndrome. Int J Med Sci 2004;1:152–64.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–95.

Brown

, Qaqish

. Antiretroviral therapy and the prevalence of steopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165–74.

Qaqish

, Sims

. Bone disorders associated with the human mmunodeficiency virus: pathogenesis and management. Pharmacotherapy 2004;24:1331–46. DOI 10.1592/phco.24.14.1331.43150

Bruera

, Luna

, David

et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003;17:1917–23.

Teichmann

, Stephan

, Lange

et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003;46: 2217. DOI 10.1053/jinf.2002.1109

Schambelan

, Benson

, Carr

et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257–75.

National Osteoporosis Foundation. 2003. Treatment guidelines. www.nof.org/physguide/impact_and_overview.htm#synopsis (accessed 2007 Jul 8).

10.

Fairfield

, Rnkelstein

, Klibanski

, Grinspoon

. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 2001;86:2020–6.

11.

Arnsten

, Freeman

, Howard

et al. Decreased bone mineral ensity and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007;21:617–23.

12.

Agents that affect bone mineral homeostasis. Antiviral agents. In: Katsung

. Basic & clinical pharmacology. 10th ed. New York: The McGraw-Hill Companies, 2001:716–32,801-27.

13.

Bartlett

, Lane

, eds. US DHHS guidelines for the use of ntiretroviral agents in HIV-1 adults and adolescents. December 1, 2007 (accessed via: http://aidsinfo.nih.gov) (accessed 2008 Jan 4).

14.

Clay

, Lam

. Testosterone replacement therapy for bone loss revention in HIV-infected males. Ann Pharmacother 2003;37:582–5. DOI 10.1345/aph.lC345

15.

Eichner

, Lloyd

, Timpe

. Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 2003;37:711–24. DOI 10.1345/aph.lC246

16.

Package insert. Evista (raloxifene). Indianapolis: Eli Lilly and Company, September 2007.

17.

Sambrook

, Guesens

, Ribot

et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004;255:503–11. DOI 10.1111/j.1365-2796.2004.01317.X

18.

Package insert. Miacalcin (calcitonin salmon) nasal spray. East Hanover, NJ: Novartis, June 2006. www.drugs.com/MMX/Alfacalcidol.html (accessed 2008 Jan 8).

19.

Dursun

, Dursun

, Yalcin

. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 2001;55:505–9.

20.

Package insert. Forteo (teriparatide). Indianapolis: Eli Lilly and Company, April 2007.

21.

Crans

, Silverman

, Genant

et al. Association of severe vertebral fractures with reduced quality of life. Arthritis Rheum 2004;50:4028–34. DOI 10.1002/art.20671

22.

Body

, Gaich

, Scheele

et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metabol 2002;87:4528–35. DOI 10.1210/jc.2002-020334

23.

Saag

, Shane

, Boonen

et al. Teriparatide or alendronate in gluco-corticoid-induced osteoporosis. N Engl J Med 2007;357:2028–39.

24.

Canalis

, Giustina

, Bilezikian

. Mechanism of anabolic therapies for osteoporosis. N Engl J Med 2007;357:905–16.

25.

Finkelstein

, Leder

, Burnett

et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metabol 2006;91:2882–7. DOI 10.1210/jc.2006-0190

26.

Iwamoto

, Takeda

, Sato

et al. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. Yonsei Med J 2005;46:750–8.

27.

Package insert. Actonel (risedronate) Cincinnati, OH: Aventis Pharmaceuticals Inc., May 2007.

28.

Package insert. Boniva (ibandronate sodium) tablets. Nutley, NJ: Roche Laboratories Inc., August 2006.

29.

Package insert. Fosamax (alendronate sodium) tablets. Whitehouse Station, NJ: Merck & Co., Inc., April 2004.

30.

Adachi

, Saag

, Delmas

et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202–11. DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W

31.

Kushida

, Shiraki

, Nakamura

et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 2004;22:462–8. DOI 10.1007/s00774-004-0508-0

32.

Lanza

, Schwartz

, Sahba

et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000;95:3112–7. DOI 10.1111/j.1572-0241.2000.03258.x

33.

Guaraldi

, Orlando

, Madeddu

et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004;5:269–77.

34.

Mondy

, Powderly

, Claxton

et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infections. J Acquir Immune Defic Syndr 2005;28:426–31.

35.

McComsey

, Kendall

, Tebas

et al. Alendronate with calcium and vitamin D supplementation is superior to calcium and vitamin D alone in the management of decreased bone mineral density in HIV. AIDS 2007;30:2473–82.

36.

Negredo

, Martinez-Lopez

, Paredes

et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005;19:341–50.

37.

Orwoll

, Ettinger

, Weiss

et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604–10.

38.

Ringe

, Faber

, Dorst

. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252–5.

39.

Cooper

, Drake

, Brankin

et al. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896–905. Epub 9 Jun 2006. DOI 10.111l/j.1742-1241.2006.01059.x

40.

Emkey

, Koltun

, Beusterien

et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–203. DOI 10.1185/030079905X74862

41.

Greenspan

, Nelson

, Trump

et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer a randomized trial. Ann Intern Med 2007;20:416–24.

42.

Cortet

, Bera-Louville

, Gauthier

et al. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. Effect of adding hormone replacement therapy. Joint Bone Spine 2001;68:410–5. DOI 10.1016/S1297-319X(01)00297-4

43.

Hosking

, Adami

, Felsenberg

et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003;19:383–94. DOI 10.1185/030079903125002009

44.

Seba

, Bonnick

, Kagan

et al. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 2004;20:2031–41. DOI 10.1185/030079904X16768

45.

Bonnick

, Saag

, Kiel

et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91:2631–7. Epub 2006 Aug 24. DOI 10.1210/JC.2005-2602

46.

Rosen

, Hochberg

, Bonnick

et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141–51. Epub 2004 Sep 9. DOI 10.1359/JBMR.040920

47.

Walgreens. www.walgreens.com/library/finddrug/druginfosearch.jsp (accessed 2007 Jul 16).

48.

Halkin

, Dushenat

, Silverman

et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2007;41:29–34. Epub 26 Dec 2006. DOI 10.1345/aph.lH218

49.

Package insert. Zometa (zoledronic acid). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2007.

50.

Saag

, Lindsay

, Kriegman

et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40:1238–43. Epub 2007 Feb 8. DOI 10.1016/j.bone2007.01.016

51.

Ringe

, Dorst

, Faber

et al. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 200434:110–3. DOI 10.1007/s00296-003-0388-y

52.

Jacobs

, de Nijs

, Lems

et al. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol 2007;34:1051–7. Epub 2007 Apr 1.

53.

de Nijs

, Jacobs

, Lems

et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675–84.

54.

Ones

, Schacht

, Dukas

et al. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover n postmenopausal osteoporosis: a two-year, randomized, multiarm, controlled trial. Internet J Epidemiol 2007; 4. www.ispub.com/ostia/index.php?xmlFilePath=journals/ije/vol4nl/bone.xml (accessed 2008 Jan 8).

55.

Ringe

, Farahmand

, Schacht

et al. Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 2007;27:425–34.

56.

Rhee

, Kang

, Min

et al. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean ostmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int 2006;17:1801–7. Epub 2006 Sep 26. DOI 10.1007/S00198-006-0200-4

57.

Reginster

, Deroisy

, Jupsin

. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Drugs Today 2003;39:89–101. DOI 10.1358/dot.2003.39.2.799416

58.

Meunier

, Roux

, Seeman

et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal steoporosis. N Engl J Med 2004;350:459–68.

59.

Bruyere

, Roux

, Detilloux

et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007;92:3076–81. Epub 2007 Jun 12. DOI 10.1210/jc.2006-2758

60.

Blake

, Fogelman

. The correction of BMD measurements for bone strontium content. J Clin Densitom 2007;10:259–65. Epub 2007 Jun 1. DOI 10.1016/j.jocd.2007.03.102

61.

Bonnick

, Broy

, Kaiser

et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin 2007;23:1341–9. DOI 10.1185/030079907X188035.

62.

National Osteoporosis Foundation. 1999. Osteoporosis report. www.nof.org/prevention/calcium_supplements (accessed 2007 8 Jul).

63.

Seattle Treatment Education Project. Calcium may offer hope to diarrhea sufferers. 2000. The Body. www.thebody.com/content/treat/art2006.html (accessed 18 Jul 2007).

64.

Madeddu

, Spanu

, Solinas

et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004;48:39–48.

65.

Kiralti

, Srinivas

, Perkash

et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001;57:127–32. DOI 10.1016/S0090-4295(00)00895-5

66.

Dolan

, Carpenter

, Grinspoon

. Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women. J Acquir Immune Defic Syndr 2007;45:161–7.

67.

Package insert. Androgel (testosterone transdermal system). Marietta, GA: Unimed Pharmaceuticals, April 2007.

68.

Bruder

, Ma

, Wing

et al. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom 2006;9:431–7. Epub 2006 Sep 6.

69.

Shimon

, Eshed

, Doolman

et al. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporosis Int 2005;16: 1591–6. Epub 2005 Mar 15. DOI 10.1007/s00198-005-1879-3